Status:

TERMINATED

Carbohydrates Under Target for Type 1 Diabetes Management

Lead Sponsor:

McGill University

Conditions:

Type 1 Diabetes

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Recently there has been an increased interest in limiting intake of carbohydrates (CHO) for improving long term health. While healthcare professionals (HCPs) are sometimes reluctant to limit the CHO i...

Eligibility Criteria

Inclusion

  • Duration of Type 1 Diabetes \> 12 months
  • On intensive insulin therapy for \> 6 months
  • Own a smartphone or tablet to use two mobile applications : Keenoa and Piezo: Achieve the Guidelines!

Exclusion

  • Known gastroparesis (clinical diagnosis)
  • Advanced kidney disease (eGFR \< 50 mL/min)
  • Known significant liver disease (e.g., cirrhosis, active hepatitis, liver transplantation)
  • Recent (\< 6 months) major cardiovascular even (e.g. myocardial infarction, cerebrovascular accident, major revascularization, etc.)
  • Pregnancy (ongoing or planned in the next 6 months)
  • Breastfeeding
  • Severe hypoglycemia episodes or ketoacidosis in the 4 weeks prior to recruitment
  • Claustrophobia or presence of metal devices/implants in the body

Key Trial Info

Start Date :

October 15 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 23 2020

Estimated Enrollment :

8 Patients enrolled

Trial Details

Trial ID

NCT04084418

Start Date

October 15 2019

End Date

March 23 2020

Last Update

February 24 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Institut de recherches cliniques de Montréal

Montreal, Quebec, Canada, H2W1R7